Cytokinetics (CYTK) Other financing activities (2010 - 2026)

Cytokinetics (CYTK) has reported Other financing activities for 12 consecutive years, with $11.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities rose 48.29% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $39.7 million (up 27.43% YoY), while the FY2025 annual figure was $36.0 million, down 32.14% from the prior year.
• Other financing activities retreated to $11.3 million in Q1 2026 per CYTK's latest filing, from $14.6 million in the prior quarter.
• Across five years, Other financing activities topped out at $29.5 million in Q1 2024 and bottomed at -$12.4 million in Q4 2023.
• Historically, Other financing activities has averaged $6.9 million across 5 years, with a median of $6.3 million in 2024.
• Annual changes were most pronounced in 2023 — Other financing activities slumped 443.47% — and 2024, when it jumped 732.59%.
• Cytokinetics' Other financing activities stood at $3.6 million in 2022, then plunged by 443.47% to -$12.4 million in 2023, then jumped by 152.44% to $6.5 million in 2024, then jumped by 126.05% to $14.6 million in 2025, then fell by 22.54% to $11.3 million in 2026.
• Business Quant data shows CYTK's Other financing activities at $11.3 million in Q1 2026, $14.6 million in Q4 2025, and $21.3 million in Q3 2025.